retatrutide nonalcoholic fatty liver disease trial Current therapies and new developments in NASH retatrutide nonalcoholic fatty liver disease – Oligonucleotide therapies for nonalcoholic steatohepatitis

Medication is a powerful tool, but our programs in Southlake are holistic

In terms of renoprotective effects, SGLT2 inhibitors were found to increase sodium delivery to the macula densa and thus restore the tubuloglomelural feedback

George Koob, director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), have expressed concern over the underutilization of FDA-approved medications, like naltrexone, for treating AUD

This study has several strengths, including assessment of a large, real-world dataset and the selection of study periods that represent the rapidly evolving treatment landscape for people with CKD and type 2 diabetes

Diabetes 69 , 25892602 (2020)